Antithymocyte Globulin in Renal Transplant Recipients: A Clinical Trial

Jeremiah G. Turcotte; Nicholas J. Feduska; Richard F. Haines; Duane T. Freier; Paul W. Gikas; Franklin D. McDonald; Arthur G. Johnson; Roger M. Morrell; Norman W. Thompson

doi:10.1001/archsurg.1973.01350160102016

Antithymocyte Globulin in Renal Transplant Recipients: A Clinical Trial

Jeremiah G. Turcotte, Nicholas J. Feduska, Richard F. Haines, Duane T. Freier, Paul W. Gikas, Franklin D. McDonald, Arthur G. Johnson, Roger M. Morrell, Norman W. Thompson

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Thirty-six intrafamilial and 35 cadaveric transplants performed consecutively between June 1969 and March 1971 were prospectively randomized into a control group and one treated with horse antihuman thymocyte globulin (HATG). All histocompatible related allografts are functioning regardless of whether HATG was used. Two year life-table survival for incompatible related grafts is 85.7% for HATG treated vs 58.4% for concurrent control grafts, while there was no difference in transplant survival of cadaveric grafts whether or not HATG was administered. Significantly fewer rejection episodes occurred in HATG cadaveric grafts. No differences in renal function, renal histologic findings, infections and other complications, or steroid requirements were noted when HATG-treated recipients were compared with control patients.

Original language	English (US)
Pages (from-to)	484-488
Number of pages	5
Journal	Archives of Surgery
Volume	106
Issue number	4
DOIs	https://doi.org/10.1001/archsurg.1973.01350160102016
State	Published - Apr 1973
Externally published	Yes

Access

10.1001/archsurg.1973.01350160102016

OpenUrl availability

Full text

Cite this

@article{015efff6f6a447058f665603381f65d1,

title = "Antithymocyte Globulin in Renal Transplant Recipients: A Clinical Trial",

abstract = "Thirty-six intrafamilial and 35 cadaveric transplants performed consecutively between June 1969 and March 1971 were prospectively randomized into a control group and one treated with horse antihuman thymocyte globulin (HATG). All histocompatible related allografts are functioning regardless of whether HATG was used. Two year life-table survival for incompatible related grafts is 85.7% for HATG treated vs 58.4% for concurrent control grafts, while there was no difference in transplant survival of cadaveric grafts whether or not HATG was administered. Significantly fewer rejection episodes occurred in HATG cadaveric grafts. No differences in renal function, renal histologic findings, infections and other complications, or steroid requirements were noted when HATG-treated recipients were compared with control patients.",

author = "Turcotte, {Jeremiah G.} and Feduska, {Nicholas J.} and Haines, {Richard F.} and Freier, {Duane T.} and Gikas, {Paul W.} and McDonald, {Franklin D.} and Johnson, {Arthur G.} and Morrell, {Roger M.} and Thompson, {Norman W.}",

year = "1973",

month = apr,

doi = "10.1001/archsurg.1973.01350160102016",

language = "English (US)",

volume = "106",

pages = "484--488",

journal = "Archives of Surgery",

issn = "0004-0010",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - Antithymocyte Globulin in Renal Transplant Recipients

T2 - A Clinical Trial

AU - Turcotte, Jeremiah G.

AU - Feduska, Nicholas J.

AU - Haines, Richard F.

AU - Freier, Duane T.

AU - Gikas, Paul W.

AU - McDonald, Franklin D.

AU - Johnson, Arthur G.

AU - Morrell, Roger M.

AU - Thompson, Norman W.

PY - 1973/4

Y1 - 1973/4

N2 - Thirty-six intrafamilial and 35 cadaveric transplants performed consecutively between June 1969 and March 1971 were prospectively randomized into a control group and one treated with horse antihuman thymocyte globulin (HATG). All histocompatible related allografts are functioning regardless of whether HATG was used. Two year life-table survival for incompatible related grafts is 85.7% for HATG treated vs 58.4% for concurrent control grafts, while there was no difference in transplant survival of cadaveric grafts whether or not HATG was administered. Significantly fewer rejection episodes occurred in HATG cadaveric grafts. No differences in renal function, renal histologic findings, infections and other complications, or steroid requirements were noted when HATG-treated recipients were compared with control patients.

AB - Thirty-six intrafamilial and 35 cadaveric transplants performed consecutively between June 1969 and March 1971 were prospectively randomized into a control group and one treated with horse antihuman thymocyte globulin (HATG). All histocompatible related allografts are functioning regardless of whether HATG was used. Two year life-table survival for incompatible related grafts is 85.7% for HATG treated vs 58.4% for concurrent control grafts, while there was no difference in transplant survival of cadaveric grafts whether or not HATG was administered. Significantly fewer rejection episodes occurred in HATG cadaveric grafts. No differences in renal function, renal histologic findings, infections and other complications, or steroid requirements were noted when HATG-treated recipients were compared with control patients.

UR - http://www.scopus.com/inward/record.url?scp=0015608076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015608076&partnerID=8YFLogxK

U2 - 10.1001/archsurg.1973.01350160102016

DO - 10.1001/archsurg.1973.01350160102016

M3 - Article

C2 - 4572345

AN - SCOPUS:0015608076

SN - 0004-0010

VL - 106

SP - 484

EP - 488

JO - Archives of Surgery

JF - Archives of Surgery

IS - 4

ER -

Antithymocyte Globulin in Renal Transplant Recipients: A Clinical Trial

Abstract

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this